Subacute cutaneous lupus and neonatal lupus are closely associated with the presence of anti-Ro (SSA) autoantibodies, but
Introduction
The majority of patients with subacute cutaneous lupus erythematosus (SCLE)' and with neonatal lupus erythematosus (NLE) have antibodies to the Ro (SSA) antigen (1, 2) . In NLE, these anti-Ro (SSA) autoantibodies are maternal in origin and cross the placenta. Their presence in the affected neonate's serum correlates well with disease activity in the skin. The disease activity generally resolves as the antibody titer decreases, both disappearing by about 6 mo of age. These observations have led to the proposal that anti-Ro (SSA) autoantibodies may play an important, and possibly direct, role in the disease process in SCLE and cutaneous neonatal lupus.
UIRNP were not detected. In 1983 she developed annular, scaly, erythematous plaques on sun-exposed skin of the arms. The clinical appearance was typical of subacute cutaneous lupus lesions. The biopsy of involved skin showed basal cell damage and a superficial mononuclear cell infiltrate, consistent with subacute cutaneous lupus. A biopsy from involved skin was also examined by immunofluorescence techniques. These lesions resolved after -2 mo without systemic treatment and have recurred only infrequently, after sun exposure. No residual scarring or pigmentary changes were seen. She had arthralgias for -2 mo during 1984. Otherwise, she had no evidence of systemic lupus erythematosus (SLE), and did not satisfy the revised diagnostic criteria of the American Rheumatism Association (ARA) for this disorder (8) .
Her first child, born in 1980 after an uncomplicated pregnancy, developed skin lesions of neonatal lupus at 8 wk of age after sun exposure. The lesions appeared as annular, scaly, erythematous plaques with mild central epidermal atrophy on the face, arms, and legs. A skin biopsy processed for hematoxylin and eosin examination and immunofluorescence examination was interpreted as consistent with lupus erythematosus. These lesions resolved by -6 mo of age. They recurred at 7 mo ofage after another episode ofsun exposure, but cleared up after 2 wk and did not recur.
A second child, born in 1981, developed annular, scaly, erythematous lesions on the face at 7 wk of age, despite careful sun protection (9) . A skin biopsy processed for hematoxylin and eosin examination and immunofluorescence examination was consistent with lupus erythematosus. The lesions had resolved at the time of follow-up at 8 mo of age.
Patient 2 had hypergammaglobulinemic purpura and satisfied the ARA revised criteria for the diagnosis of SLE. She did not have any children, nor did she have a skin rash other than purpura. The patient had a positive antinuclear antibody on an HEp-2 substrate at a titer of 120 and an anti-Ro (SSA) precipitin. She had no anti-single stranded DNA by the Farr assay (10) and no anti-double stranded DNA by Crithidia luciliae( I 1). In solid phase assays performed as described (6), she had 6.9 X 106 U ofanti-Ro (SSA) (-1.4 mg/ml ofserum). Neither anti-La (SSB) nor anti-URNP was detectable in her serum.
Antigen purification. Ro (SSA) antigen was purified to homogeneity as modified from the published description ( 12) MO) , washed, and incubated with the para-nitrophenylphosphate substrate. The reaction was monitored at 405 nm using a Microelisa reader (Dynatec Laboratories Inc., Alexandria, VA). As a test of specificity, appropriate dilutions of sera were preincubated with 10 ,g/ml of the RNA protein being tested to block antibody reactivity.
Assays of anti-Ig activity. For testing rheumatoid factor activity against human Ig, a standard Latex agglutination test (Difco Laboratories Inc., Detroit, MI) was used. A second assay for testing anti-mouse Ig activity was also applied. Total IgG purified from both sera I and 2 were coated on a microtiter dish at 5 jug/ml overnight at 40C. Nude mouse serum was added at a 1:100 dilution in PBS-TWEEN (0.02 M phosphate buffer, 0.15 M NaCl, 0.1% BSA, and 0.05% TWEEN-20, pH 7.4) and incubated 3 h at room temperature. Anti-mouse IgG conjugated to alkaline phosphatase (Sigma Chemical Co.), diluted 1:1,000 in PBS-TWEEN, was added to the plate and incubated 3 h at room temperature. Development with substrate proceeded as described above.
Skin grafting. Male and female BALB/c nude athymic mice (Harlan Sprague Dawley, Inc., Indianapolis, IN) and male and female SCID mice (Fox Chase Cancer Institute, Philadelphia, PA) were grafted with human skin as described by Krueger and Emam (13) . The source of skin was tissue that would otherwise have been discarded after abdominoplasty or mammoplasty and was obtained in accordance with the policies of the Institutional Review Board for human investigation. The skin donors were all female and were apparently healthy. No anti-Ro (SSA) activity was detected in nude mouse serum. Grafts were allowed to heal for 1 mo before use.
Antibodi' injections and skin biopsies. Antisera and purified antibodies were injected into the peritoneal cavity ofgrafted mice. 1 d later the human skin grafts were removed, frozen, and stored at -70'C until further use. Direct immunofluorescence for human IgG and mouse IgG was performed by a standard method ( 14) .
Case descriptions of subacute cutaneous lupus patients. Lesional skin from five patients with SCLE was examined. Two ofthese patients were patient 1, described above, and one of her children. The remaining three patients were adults, one female and two males. All patients had subacute cutaneous lupus lesions on clinical examination. Except for transient arthralgias in patient 1, none of these patients had other symptoms and none met the ARA criteria for SLE. All patients had anti-Ro (SSA) antibodies. None had detectable anti-DNA, -Sm, -RNP, or -La (SSB) autoantibodies.
Results
When grafted nude mice and SCID mice were injected with 0.1 ml anti-Ro (SSA) sera, human IgG antibodies could be detected in the skin grafts. The predominant finding in all grafts was a particulate deposition of IgG in the epidermis which on occasion obscured the epidermal-dermal junction. In most areas the epidermal staining appeared to be predominantly cytoplasmic ( Fig. 1 A) , although some epidermal cells seemed to be outlined by the antibody deposition. Many areas had nuclear staining in addition to cytoplasmic staining (Fig. 1  B) . In occasional areas there was accentuation of IgG deposition at the basal cell layer (Fig. 1 C) . Only rarely was there IgG deposition under the basement membrane zone in the absence of epidermal deposition (Fig. 1 D) . All of these patterns of staining could, and often did, occur within the same biopsy. Much less striking than the epidermal IgG deposits was occasional particulate IgG deposition in the dermis, often visible around blood vessels. The spectrum of immunofluorescent findings in the animal model parallels that which we have observed in patients with SCLE and NLE (Fig. 2) . Of five patients whose lesions have been examined, all five had a particulate deposition of IgG that was predominantly epidermal. In most areas of the skin biopsies, particulate cytoplasmic staining was seen (Fig. 2  A) , with or without particulate nuclear staining (Fig. 2 B) . Fewer areas of the biopsies showed staining predominantly in the basal layer of the epidermis (Fig. 2 C) . Deposits under the basement membrane zone (lupus band) were not seen in these patients. In several areas there was a minor particulate deposition of IgG in the dermis, which often appeared around blood vessels. Two of the five patients examined were patient 1 (Fig.   2 B) , whose anti-Ro (SSA) autoantibodies were used in these studies, and a daughter ofpatient 1 (Fig. 2 C) , who had cutaneous neonatal lupus. (The skin biopsy from her other affected daughter was not available for review.)
Particulate epidermal staining has been frequently noted in patients with mixed connective tissue disease, but has been assumed to be an artifact (15) . It was hypothesized that, during sectioning, the blade cutting through the dermis would drag serum from the dermis across the epidermis. Anti-UIRNP antibodies in the serum, present in high titers in mixed connective tissue disease, would then bind to the epidermis during sectioning. To address the possibility that the epidermal staining seen with anti-Ro (SSA) is an artifact of sectioning, we apposed a biopsy of human skin from an animal injected with anti-Ro (SSA) to a biopsy of normal human skin. The sections were cut so that the blade cut through the dermis ofthe grafted skin, then the graft's epidermis, the normal epidermis, and the normal dermis (Fig. 3 A) . If the epidermal staining we observed is an artifact of sectioning, we would expect that the cryostat blade would drag serum not only across the graft epidermis but across the normal epidermis as well. We would then see IgG deposition in the graft epidermis and normal epidermis. What we actually observed was IgG deposition in the human skin graft but not in the normal epidermis, verifying that the epidermal staining is not artifactual (Fig. 3 B) .
As in previous experiments, when anti-Ro (SSA) serum was injected into grafted mice, there was no detectable human IgG deposition in mouse skin (3). The reason for this lack of IgG deposition probably relates to the fact that human antiRo (SSA) antibodies frequently do not bind murine Ro (SSA) antigen (3). There was no evidence of human IgG deposition in the human skin grafts of over 20 mice who were injected with normal human serum in these and previous experiments.
As an additional test of the specificity of the IgG deposited in the human skin graft, serum from patient 2 was absorbed with the Ro (SSA) affinity column, thereby removing 80% of the anti-Ro (SSA) binding activity. When two nude mice were injected with 0. 1 ml ofabsorbed sera, the IgG deposition in the human skin grafts was markedly diminished (Fig. 4) .
Further experiments to determine the specificity ofthe IgG deposited in the human skin grafts were performed using affinity-purified anti-Ro (SSA) antibodies. When 1.2 mg of affinity-purified anti-Ro (SSA) IgG from patient 2 was injected, antibody binding was readily detectable in the human skin graft in the same pattern previously observed with whole serum (figure not shown).
Immunofluorescence examination of the human skin grafts for the deposition of mouse Ig showed mouse IgG to be present in the human skin grafted onto nude mice. To determine ifanti-Ro (SSA) antibodies were binding to the mouse Ig present in the skin grafts by anti-IgG activity found in anti-Ro (SSA) sera (5), mice with SCID were studied. These mice had T and B cell deficiencies and synthesized virtually no Ig (16) . As anticipated, no mouse IgG was detected by immunofluorescence in human skin grafts on SCID mice. Anti-Ro (SSA) injected into the grafted SCID mice produced the same immunofluorescence pattern as seen in nude mice, establishing that anti-Ro (SSA) was not binding via an interaction with mouse Ig. Of five grafted SCID mice injected with anti-Ro (SSA) DIRECTION serum, human IgG could be found in the skin grafts of each in the patterns as described above (see Fig. 1 ). An additional grafted SCID mouse that was injected with 1.4 mg of affinitypurified anti-Ro (SSA) antibodies from serum 1 had IgG antibody deposition in the epidermis (Fig. I A) . Further, by a solid phase assay human anti-Ro (SSA) IgG did not bind mouse Ig.
Discussion
Subacute cutaneous lupus and neonatal lupus are diseases strongly associated with the presence of anti-Ro (SSA) antibodies. About 80% of SCLE patients and 95% of neonatal lupus patients have anti-Ro (SSA) antibodies (1, 2) . Since the skin disease activity in babies with neonatal lupus coincides with the presence of anti-Ro (SSA) in the infant's serum, it has been suspected that anti-Ro (SSA) antibodies may be involved in the disease process. Ro (SSA) antigen has been demonstrated to be present in normal skin (17, 18) and may appear on the cell surface of cultured keratinocytes (19) .
We have previously shown in an animal model, the nude mouse with grafted human skin, that human IgG could be found in the skin grafts after parenteral injection of human anti-Ro (SSA) serum (3) . Antibody binding was augmented somewhat by prior exposure of the grafts to ultraviolet light, a finding consistent with previous studies in cultured keratinocytes (19) and with the clinical observation that SCLE and NLE patients with anti-Ro (SSA) autoantibodies frequently are photosensitive (1, 20) . It was hypothesized that the antibody binding observed in the animal model (3) was due to anti-Ro (SSA) antibodies, since IgG in other sera without anti-Ro (SSA) did not bind the human skin graft. In those experiments, however, the evidence that antibody binding was due to anti-Ro (SSA) was indirect. Also, even if the antibody binding were due to anti-Ro (SSA), the possibility remained that anti-Ro (SSA) antibodies were binding in the skin simply because of a possible affinity of anti-Ro (SSA) antibodies for mouse 1g.
In the present experiments we demonstrated by using affinity-purified antibodies and serum preabsorbed with purified Ro (SSA) antigen that anti-Ro (SSA) antibodies do indeed bind to the human skin. By repeating the anti-Ro (SSA) sera injections in grafted SCID mice, we showed that anti-Ro (SSA) antibody binding occurs even in the absence ofmouse Ig and therefore cannot be explained by anti-Ig activity.
It seems likely that the antibody deposition observed represents in situ binding of anti-Ro (SSA) antibodies to Ro (SSA) antigen that is present in the skin, rather than a nonspecific deposit of circulating Ro (SSA)-anti-Ro (SSA) immune complexes. For one thing, affinity-purified antibodies were used in some experiments, so that immune complexes were not preformed before injection. After injection, it was unlikely that immune complexes would form in the circulation because of the lack of availability of antigen that would bind the human antibodies. The sera used did not contain antibodies that bound mouse antigens, and the amount of circulating human Ro (SSA) antigen contributed by the human skin graft must be small. Further, antibody binding was observed in the human skin graft but not in immediately adjacent mouse skin. This indicates that the antibodies bound specifically a human antigen and argues against the possibility that there was a nonspecific deposit of preformed immune complexes.
Most descriptions of the immunofluorescent findings in the skin in lupus erythematosus have focused on the deposition of Ig under the basement membrane zone (21, 22) . A granular deposition of Ig under the basement membrane zone is often considered a sine qua non for a positive immunofluorescence test for lupus erythematosus, referred to by many authors as a lupus band test. The specific immunofluorescence findings in SCLE and NLE lesions have generally not been detailed, and the expected presence or absence of epidermal staining in these diseases cannot be fully assessed by examining previous reports. In our animal model it is striking that the most common immunofluorescence finding is IgG deposition in the epidermis rather than under the basement membrane zone. Although this pattern ofdeposition is different from that generally described in lupus erythematosus, it is nevertheless identical to that which we have seen in five of five SCLE and NLE skin biopsies examined by direct immunofluorescence. Skin biopsies from three of these patients are shown in Fig. 2 . As Fig. 3 shows, epidermal staining is not an artifact produced during tissue sectioning. SCLE and NLE are clinically distin- guishable from discoid lupus (DLE) and skin lesions of SLE (23, 24) , and SCLE can be distinguished histologically from DLE (25) . In addition, the majority of SCLE and NLE patients have anti-Ro (SSA) antibodies, which is not the case with DLE and SLE. It seems likely that the distinctive immunofluorescence pattern we have observed in the human skin grafts and SCLE lesions is the result of specific binding of anti-Ro (SSA) antibodies in the skin.
SCLE is the form of cutaneous lupus erythematosus in adults that most closely resembles the skin lesions of NLE, which is why patient 1 was chosen for this study. Presumably the same maternal antibodies have produced indistinguishable skin lesions in both mother and offspring. This data shows that the purified anti-Ro (SSA) produced the same Ig pattern in the human skin graft as found in the lesional skin of patient 1 Though the findings presented here support the potential importance of anti-Ro (SSA) in certain types of cutaneous lupus, they do not address the possible roles of other autoantibodies in SCLE and NLE. In fact, it seems likely that in some instances anti-La (SSB) or anti-URNP may contribute to NLE. Cutaneous NLE has been noted in at least one patient who had anti-La (SSB) but not apparently anti-Ro (SSA) (26) , and in two anti-U1RNP-positive infants who did not have anti-Ro (SSA) antibodies as measured by a sensitive solid phase assay (27) . It is of interest that anti-La (SSB) and anti-UIRNP antibodies, like anti-Ro (SSA) antibodies, have also been shown to bind to viable cultured human keratinocytes (18, 28 ).
Our results demonstrate that anti-Ro (SSA) autoantibodies, the autoantibodies most consistently found in SCLE and NLE, can bind specifically to the skin, particularly to the epidermis. The pattern ofbinding seen is identical to that we have observed in SCLE and NLE skin lesions. These findings establish that anti-Ro (SSA) antibodies bind to Ro (SSA) or a crossreacting antigen in the skin and may be directly implicated in the disease process producing subacute cutaneous lupus and cutaneous neonatal lupus.
